Lenvima FDA Approval History
Reviewed by J.Stewart BPharm. Last updated on Sep 18, 2019.
FDA Approved: Yes (First approved February 13, 2015)
Brand name: Lenvima
Generic name: lenvatinib
Dosage form: Capsules
Company: Eisai Inc.
Treatment for: Thyroid Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma, Endometrial Cancer
Lenvima (lenvatinib) is a multiple receptor tyrosine kinase (RTK) inhibitor for the treatment of thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma.
- Thyroid Cancer
- for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).
- Renal Cell Carcinoma
- in combination with everolimus, for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior antiangiogenic therapy.
- Hepatocellular Carcinoma
- for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
- Endometrial Carcinoma
- in combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.
Development Timeline for Lenvima
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.